Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov127710.25208/vdv1277REVIEWSОБЗОР ЛИТЕРАТУРЫReview ArticleModern understanding of the pathogenesis of basal cell skin cancerСовременное представление о патогенезе базальноклеточного рака кожиhttps://orcid.org/0000-0001-6132-56321149-2097SaytburkhanovR. R.СайтбурхановР. Р.
Russian Federation

dermatovenereologis

врач-дерматовенеролог

rifat03@yandex.ruhttps://orcid.org/0000-0002-7625-05038771-4990KubanovA. A.КубановА. А.
Russian Federation

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

д.м.н., профессор, член-корреспондент РАН

alex@cnikvi.ruhttps://orcid.org/0000-0003-3662-99548721-9424KondrakhinaI. N.КондрахинаИ. Н.
Russian Federation

MD, Cand. (Sci.) Med.

к.м.н.

kondrakhina77@gmail.comhttps://orcid.org/0000-0003-4169-41287634-5521PlakhovaX. I.ПлаховаК. И.
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

plahova@cnikvi.ruState Research Center of Dermatovenereology and CosmetologyГосударственный научный центр дерматовенерологии и косметологии2312202197538511509202117112021Copyright ©; 2021, Saytburkhanov R.R., Kubanov A.A., Kondrakhina I.N., Plakhova X.I.Copyright ©; 2021, Сайтбурханов Р.Р., Кубанов А.А., Кондрахина И.Н., Плахова К.И.2021Saytburkhanov R.R., Kubanov A.A., Kondrakhina I.N., Plakhova X.I.Сайтбурханов Р.Р., Кубанов А.А., Кондрахина И.Н., Плахова К.И.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1277

The incidence of basal cell skin cancer is increasing worldwide. The initiation and progression of basal cell skin cancer is due to the interaction of environmental factors and the patient's genetic characteristics. Aberrant activation of the transmission of the Hedgehog signaling pathway is the main pathogenetic pathway of carcinogenesis.

Since basal cell skin cancer is manifested by significant variability of morphological structure, aggressiveness and response to treatment, the disclosure of the molecular genetics of pathogenesis will become the basis for developing new approaches and increasing the effectiveness of treatment, as well as overcoming tumor resistance to treatment.

To search for the necessary literature, the PubMed, MedLine, Web of Science and RSCI databases were used.

В настоящее время заболеваемость базальноклеточным раком кожи растет во всем мире. Возникновение и прогрессирование базальноклеточного рака кожи обусловлено взаимодействием факторов окружающей среды и генетическими особенностями пациента. Основным патогенетическим путем канцерогенеза является аберрантная активация передачи сигнального пути Hedgehog.

Поскольку базальноклеточный рак кожи проявляется значительной вариабельностью клинической картины, течения заболевания и результативности терапии, выявление значимых звеньев молекулярной генетики его патогенеза станет основанием для разработки новых подходов и повышения эффективности лечения, а также преодоления резистентности опухоли к проводимой терапии.

Для поиска литературы использованы базы данных PubMed, MedLine, Web of Science и РИНЦ.

basal cell carcinomapathomechanismmicroRNAбазальноклеточный рак кожипатогенезмикроРНКThe work was done through financing at the place of work of the authors.Работа выполнена и опубликована за счет финансирования по месту работы авторов.Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). 2020. [Kaprin AD, Starinskij VV, Shahzadova AO. Zlokachestvennye novoobrazovanija v Rossii v 2019 godu (zabolevaemost' i smertnost'). 2020 (In Russ.)]Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. Dermatol Ther (Heidelb). 2017;7(Suppl 1):5–19. doi:10.1007/s13555-016-0165-ySreekantaswamy S, Endo J, Chen A, Butler D, Morrison L, Linos E. Aging and the treatment of basal cell carcinoma. Clin Dermatol. 2019;37(4):373–378. doi: 10.1016/j.clindermatol.2019.06.004Fania L, Mazzanti C, Campione E, Candi E, Abeni D, Dellambra E. Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention. Int J Mol Sci. 2019;20(23):5946. doi: 10.3390/ijms20235946López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. doi: 10.1016/j.cell.2013.05.039Snaidr VA, Damian DL, Halliday GM. Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Exp Dermatol. 2019;28 Suppl 1:15–22. doi: 10.1111/exd.13819Кубанов А.А., Жилова М.Б. К вопросу о потенциальных рисках канцерогенности фототерапии у больных псориазом. Вестник дерматологии и венерологии. 2014.5;60–67. [Kubanov AA, Zhilova MB. K voprosu o potencial'nyh riskah kancerogennosti fototerapii u bol'nyh psoriazom . Vestnik dermatologii i venerologii. 2014.5;60–67 (In Russ.)]Zanetti R, Rosso S, Martinez C, Nieto A, Miranda A, Mercier M, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer. 2006;94(5):743–751. doi: 10.1038/sj.bjc.6602982Kricker A, Armstrong BK, English DR, Heenan PJ. (1995). Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia. International journal of cancer, 60(4)489–494. https://doi.org/10.1002/ijc.2910600411Gallagher RP, Hill GB, Bajdik CD, Fincham S, Coldman AJ, McLean, DI. et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995;131(2):157–163.Wehner MR, Shive ML, Chren MM, Han J, Qureshi AA, Linos E. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ. 2012;345:e5909. doi: 10.1136/bmj.e5909Ferrucci LM, Cartmel B, Molinaro AM, Leffell DJ, Bale AE, Mayne ST. Indoor tanning and risk of early-onset basal cell carcinoma. J Am Acad Dermatol. 2012;67(4):552–562. doi: 10.1016/j.jaad.2011.11.940Schmidt SA, Schmidt M, Mehnert F, Lemeshow S, Sørensen HT. Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol. 2015;29(8):1545–1554. doi: 10.1111/jdv.12921Boaventura P, Oliveira R, Pereira D, Soares P, Teixeira-Gomes J. Head and neck basal cell carcinoma prevalence in individuals submitted to childhood X-ray epilation for tinea capitis treatment. Eur J Dermatol. 2012;22(2):225–230. doi: 10.1684/ejd.2012.1670Lichter MD, Karagas MR, Mott LA, Spencer SK, Stukel TA, Greenberg ER. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol. 2000;136(8):1007–1011. doi: 10.1001/archderm.136.8.1007Shore RE, Moseson M, Xue X, Tse Y, Harley N, Pasternack BS. Skin cancer after X-ray treatment for scalp ringworm. Radiat Res. 2002;157(4):410–418. doi: 10.1667/0033-7587(2002)157[0410:scaxrt]2.0.co;2Boaventura P, Pereira D, Mendes A, Batista R, da Silva, AF, Guimarães I, et al. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. J Dermatol Sci. 2014;73(1):31–39. doi: 10.1016/j.jdermsci.2013.09.002Flohil SC, van der Leest RJ, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2013;49(10):2365–2375. doi: 10.1016/j.ejca.2013.03.010Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136(12):1524–1530. doi: 10.1001/archderm.136.12.1524Wehner MR, Linos E, Parvataneni R, Stuart SE, Boscardin WJ, Chren MM. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol. 2015;151(4):382–388. doi:10.1001/jamadermatol.2014.3307Ricci F, Paradisi A, Fania L, Pallotta S, DI Lella G, Sobrino L, et al. High melanoma risk in non-melanoma skin cancer patients under age 40: a large retrospective cohort study. Ital J Dermatol Venerol. 2021;156(2):240–243. doi: 10.23736/S0392-0488.19.06276-XMarzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–179.Correia de Sá TR, Silva R, Lopes JM. Basal cell carcinoma of the skin (part 1): epidemiology, pathology and genetic syndromes. Future Oncol. 2015;11(22):3011–3021. doi: 10.2217/fon.15.246Ikehata H, Ono T. The mechanisms of UV mutagenesis. J Radiat Res. 2011;52(2):115–125. doi: 10.1269/jrr.10175Didona D, Paolino G, Bottoni U, Cantisani C. Non Melanoma Skin Cancer Pathogenesis Overview. Biomedicines. 2018;6(1):6.doi: 10.3390/biomedicines6010006Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–754. doi: 10.1038/nrc2503Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15(23):3059–3087. doi: 10.1101/gad.938601Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008;22(18):2454–2472. doi: 10.1101/gad.1693608Niyaz M, Khan MS, Mudassar S. Hedgehog Signaling: An Achilles' Heel in Cancer. Transl Oncol. 2019;12(10):1334–1344. doi: 10.1016/j.tranon.2019.07.004Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC. Understanding the Molecular Genetics of Basal Cell Carcinoma. Int J Mol Sci. 2017;18(11):2485. doi: 10.3390/ijms18112485Bakshi A, Chaudhary SC, Rana M, Elmets CA, Athar M. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. Mol Carcinog. 2017;56(12):2543–2557. doi: 10.1002/mc.22690Lee J, Platt KA, Censullo P, Ruiz i Altaba A. Gli1 is a target of Sonic hedgehog that induces ventral neural tube development. Development. 1997;124(13):2537–2552.Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–92. doi: 10.1038/34201Aszterbaum M, Rothman A, Johnson RL, Fisher M, Xie J, Bonifas JM, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol. 1998;110(6):885–888. doi:10.1046/j.1523-1747.1998.00222.xDanhof R, Lewis K, Brown M. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. Am J Clin Dermatol. 2018;19(2):195–207. doi: 10.1007/s40257-017-0319-4Nilsson M, Undèn AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci USA. 2000;97(7):3438–3443. doi: 10.1073/pnas.050467397Sheng H, Goich S, Wang A, Grachtchouk M, Lowe L, Mo R, et al. Dissecting the oncogenic potential of Gli2: deletion of an NH(2)-terminal fragment alters skin tumor phenotype. Cancer Res. 2002;62(18):5308–5316.Di Magno L, Coni S, Di Marcotullio L, Canettieri G. Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy. Biochim Biophys Acta. 2015;1856(1):62–72. doi: 10.1016/j.bbcan.2015.06.003Pietrobono S, Gagliardi S, Stecca B. Non-canonical Hedgehog Signaling Pathway in Cancer: Activation of GLI Transcription Factors Beyond Smoothened. Front Genet. 2019;10:556. doi: 10.3389/fgene.2019.00556Di Magno L, Coni S, Di Marcotullio L, Canettieri G. Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy. Biochim Biophys Acta. 2015;1856(1):62–72. doi: 10.1016/j.bbcan.2015.06.003Atwood SX, Chang AL, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol. 2012;199(2):193–197. doi: 10.1083/jcb.201207140DiDonato JA, Mercurio F, Karin M. NF-B and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379–400. doi:10.1111/j.1600-065X.2012.01099.xMazzà D, Infante P, Colicchia V, Greco A, Alfonsi R, Siler M, et al. PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling in p53-dependent response to genotoxic stress. Cell Death Differ. 2013;20(12):1688–1697. doi: 10.1038/cdd.2013.120Riobó NA, Lu K, Ai X, Haines GM, Emerson CP Jr. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci U S A. 2006;103(12):4505-4510. doi: 10.1073/pnas.0504337103Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):342–353. doi: 10.1016/j.ccell.2015.02.002Zhang H, Pasolli HA, Fuchs E. Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci U S A. 2011;108(6):2270–2275. doi: 10.1073/pnas.1019603108Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24(9):862–874. doi: 10.1101/gad.1909210Furth N, Aylon Y, Oren M. p53 shades of Hippo. Cell Death Differ. 2018;25(1):81–92. doi: 10.1038/cdd.2017.163van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development. 2009;136(19):3205–3214. doi:10.1242/dev.033910Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Grieco M, Ramires P, et al. WNT-1 expression in basal cell carcinoma of head and neck. An immunohistochemical and confocal study with regard to the intracellular distribution of beta-catenin. Anticancer Res. 2002;22(2A):565–576.El-Bahrawy M, El-Masry N, Alison M, Poulsom R, Fallowfield M. Expression of beta-catenin in basal cell carcinoma. Br J Dermatol. 2003;148(5):964–970. doi: 10.1046/j.1365-2133.2003.05240.xWatt FM, Estrach S, Ambler CA. Epidermal Notch signalling: differentiation, cancer and adhesion. Curr Opin Cell Biol. 2008;20(2):171–179. doi: 10.1016/j.ceb.2008.01.010Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol. 2014;134(1):213–220. doi: 10.1038/jid.2013.276Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33(3):416–421. doi: 10.1038/ng1099Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi: 10.1016/s0092-8674(04)000455 Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105. doi: 10.1101/gr.082701.108Sand M, Sand D, Altmeyer P, Bechara FG. MicroRNA in non-melanoma skin cancer. Cancer Biomark. 2012;11(6):253–257. doi: 10.3233/CBM-2012-0274Heffelfinger C, Ouyang Z, Engberg A, Leffell DJ, Hanlon AM, Gordon PB, et al. Correlation of Global MicroRNA Expression With Basal Cell Carcinoma Subtype. G3 (Bethesda). 2012;2(2):279–286. doi: 10.1534/g3.111.001115Sonkoly E, Lovén J, Xu N, Meisgen F, Wei T, Brodin P, et al. MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma. Oncogenesis. 2012;1(3):e3. doi: 10.1038/oncsis.2012.3Sand M, Bechara FG, Gambichler T, Sand D, Friedländer MR, Bromba M, et al. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study. Ann Oncol. 2016;27(2):332–338. doi: 10.1093/annonc/mdv551Goradel NH, Asghari MH, Moloudizargari M, Negahdari B, Haghi-Aminjan H, Abdollahi M. Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence. Toxicol Appl Pharmacol. 2017;335:56–63. doi: 10.1016/j.taap.2017.09.022Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60(2):203–212.Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015;35 Suppl(Suppl):S224-S243. doi: 10.1016/j.semcancer.2015.01.001Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438(7070):937–945. doi: 10.1038/nature04479Angara K, Borin TF, Arbab AS. Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma. Transl Oncol. 2017;10(4):650–660. doi: 10.1016/j.tranon.2017.04.007Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011;27:563–584.doi: 10.1146/annurev-cellbio-092910-154002Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007;11(6):539–554. doi: 10.1016/j.ccr.2007.04.017Bielenberg DR, Zetter BR. The Contribution of Angiogenesis to the Process of Metastasis. Cancer J. 2015;21(4):267–273. doi:10.1097/PPO.0000000000000138Sand M, Bromba A, Sand D, Gambichler T, Hessam S, Becker JC. et al. Dicer Sequencing, Whole Genome Methylation Profiling, mRNA and smallRNA Sequencing Analysis in Basal Cell Carcinoma. Cell Physiol Biochem. 2019;53(5):760–773. doi: 10.33594/000000171Pakravan K, Babashah S, Sadeghizadeh M, Mowla SJ, Mossahebi-Mohammadi M, Ataei F, et al. MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1/VEGF signaling axis in breast cancer cells. Cell Oncol (Dordr). 2017;40(5):457–470. doi: 10.1007/s13402-017-0335-7Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;20(12):1603–1614. doi: 10.1038/cdd.2013.125Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012;167(4):847–855. doi: 10.1111/j.1365-2133.2012.11022.xMa H, Pan JS, Jin LX, Wu J, Ren YD, Chen P, et al. MicroRNA-17~92 inhibits colorectal cancer progression by targeting angiogenesis. Cancer Lett. 2016;376(2):293–302. doi:10.1016/j.canlet.2016.04.011Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 2002;62(16):4773–4780.Li Y, Zhang D, Wang X, Yao X, Ye C, Zhang S, et al. Hypoxia-inducible miR-182 enhances HIF1 signaling via targeting PHD2 and FIH1 in prostate cancer. Sci Rep. 2015;5:12495. doi:10.1038/srep12495Wan C, Li Y. Integrative analysis of mRNA-miRNA-TFs reveals the key regulatory connections involved in basal cell carcinoma. Arch Dermatol Res. 2020;312(2):133–143. doi: 10.1007/s00403-019-02002-yLi Y, Cai B, Shen L, Dong Y, Lu Q, Sun S, et al. MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3. Cancer Lett. 2017;397:111–119. doi: 10.1016/j.canlet.2017.03.032Sawada Y, Nakamura M. Daily Lifestyle and Cutaneous Malignancies. Int J Mol Sci. 2021;22(10):5227. doi: 10.3390/ijms22105227Fania L, Didona D, Morese R, Campana I, Coco V, Di Pietro FR, et al. Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2020;8(11):449. doi: 10.3390/biomedicines8110449Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. (2013). U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research, 19(9); 2289–2293. doi: 10.1158/1078-0432.CCR-12-1956Casey D, Demko S, Shord S, Zhao H, Chen H, He K, et al. (2017). FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(10), 2377–2381. doi: 10.1158/1078-0432.CCR-16-2051